software for windows version 9.2 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
software for windows version 9.2
Software For Windows Version 9.2, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+for+windows+version+9%2E2/software+version+9+2/pm40339714-102-9-12
Average 90 stars, based on 1 article reviews
Software For Windows Version 9.2, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+for+windows+version+9%2E2/software+version+9+2/pm40339714-102-9-12
Average 90 stars, based on 1 article reviews
software for windows version 9.2 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Efficacy of a Smart Insulin Pen Cap for the Management of Patients with Uncontrolled Type 2 Diabetes: A Randomized Cross-Over Trial. Article Snippet: Background: We studied a smart insulin pen cap that can be plugged to several brand of insulin pens, to track insulin administration via smart-phone Bluetooth technology, with alarm/reminder system aiming.. Methods: This pilot randomized, cross-over design study assessed the use of a smart insulin pen cap in improving adherence, glycemic control and patient satisfaction in insulin-treated patients with poorly controlled type 2 diabetes.. Eighty patients on basal insulin ± oral agents with hemoglobin A1C (HbA1c) between 7.0% and 12.0% were randomized to a 12-week active phase receiving alarms/reminders and a 12-week control/masked phase without feedback. Article Title: Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial Article Snippet: SAS Software for Article Title: Silver nanoparticles enhance the mitigation of osmotic stress in Chenopodium quinoa microshoots grown under in vitro osmo-stressing conditions. Article Snippet: Data were analyzed using SAS software for Article Title: painPREDICT: first interim data from the development of a new patient-reported pain questionnaire to predict treatment response using sensory symptom profiles. Article Snippet: Objective: Sensory symptom patterns may be useful for predicting treatment response, and thus improve individual therapy in patients suffering from neuropathic pain (NeP).. Existing screening questionnaires focus predominately on neuropathic mechanisms without consideration of nociceptive mechanisms or mixed pain states.. This study aimed to develop a new questionnaire, painPREDICT, using a wide set of patient-reported descriptors potentially associated with neuropathic and nociceptive pain mechanisms, and to explore sensory symptom patterns. Article Title: Association of lipid-modifying medication with reduced mortality in bipolar disorder: A nationwide cohort study. Article Snippet: Objective: Patients with bipolar disorder face higher mortality risks from natural causes and suicide.. Lipidmodifying medications, among the most widely prescribed medications, also show potential in alleviating mood symptoms.. Limited research explores if these medications reduce all-cause, natural, and suicide mortality risks. Article Title: Comparison of clinical pharmacy specialists and usual care in outpatient management of hyperglycemia in Veterans Affairs medical centers. Article Snippet: All data analyses were performed using SAS, Article Title: Interferential current: a new option for the treatment of sexual complaints in women with premature ovarian insufficiency using systemic hormone therapy: a randomized clinical trial. Article Snippet: Objective: The aim of the study was to evaluate the efficacy of interferential current (IC) in the sexual function of women with premature ovarian insufficiency (POI) using systemic hormone therapy (HT), compared to topical estriol.. Methods: A randomized clinical trial with 40 women with POI using systemic HT, who were sexually active and referred for dyspareunia and reduction of lubrication.. The women were divided into two treatment groups for 4 weeks: IC group (eight electrotherapy sessions twice a week); or E group (estriol vaginal cream, daily application, 0.5 mg/d). |